Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Jiangsu Longteng Biotechnology is a leading Chinese life sciences company specializing in the development and manufacture of high-end raw materials for molecular diagnostics and biopharmaceutical production. The company provides a comprehensive portfolio of high-performance enzymes, including Taq polymerase, reverse transcriptase, and T7 RNA polymerase, as well as high-purity dNTPs and diagnostic antibodies. These products are essential components for quantitative PCR (qPCR), next-generation sequencing (NGS), and mRNA vaccine manufacturing. Backed by prominent investors such as IDG Capital and Legend Capital, Longteng Biotech serves a global clientele of IVD manufacturers and research institutions, focusing on the upstream supply chain for infectious disease testing, oncology diagnostics, and genetic screening.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Longteng Biotech.